Effectiveness and Safety of Adjunctive Cenobamate in People with Focal-Onset Epilepsy: Evidence from the First Interim Analysis of the BLESS Study

期刊论文
出版模式：

开放获取
发表日期：

2024年6月8日

查看全文

Simona Lattanzi,
Federica Ranzato,
Carlo Di Bonaventura,
Paolo Bonanni,
Antonio Gambardella,
Elena Tartara,
Giovanni Assenza,
Michela Procaccini,
Nathalie Falsetto,
Valentina Villano,
Gabriele Camattari,
Alessandra Ori,
Giancarlo Di Gennaro,
Alfredo D’Aniello,
Cecilia Catania,
Alessandra Morano,
Biagio Orlando,
Angela La Neve,
Teresa Francavilla,
Francesca Pia Mazzeo,
Giada Pauletto,
Marco Belluzzo,
Anna Carmen Nilo,
Alessia Peretti,
Diana Polo,
Giulia Lippa,
Marianna Nesta,
Lorenzo Ricci,
Alberto Danieli,
Elisa Osanni,
Francesco Fortunato,
Giuseppe Magro,
Laura Marino,
Ilaria Sammarra,
Carlo Andrea Galimberti,
Domenico Lomonaco,
Pietro Pignatta,
Devis Collura,
Emanuela Viglietta

摘要

Introduction

Despite new anti-seizure medications (ASMs) being introduced into clinical practice, about one-third of people with epilepsy do not reach seizure control. Cenobamate is a novel tetrazole-derived carbamate compound with a dual mechanism of action. In randomized controlled trials, adjunctive cenobamate reduced the frequency of focal seizures in people with uncontrolled epilepsy. Studies performed in real-world settings are useful to complement this evidence and better characterize the drug profile.

Methods

The Italian BLESS (“Cenobamate in Adults With Focal-Onset Seizures”) study is an observational cohort study aimed to evaluate the effectiveness, tolerability, and safety of adjunctive cenobamate in adults with uncontrolled focal epilepsy in the context of real-world clinical practice. The study is ongoing and conducted at 50 centers in Italy. This first interim analysis includes participants enrolled until June 2023 and with 12-week outcome data available.

Results

Forty participants with a median age of 36.5 (interquartile range [IQR] 26.0–47.5) years were included. The median monthly seizure frequency at baseline was 6.0 (IQR 2.5–17.3) seizures and 31 (77.5%) participants had failed four or more ASMs before cenobamate. At 12 weeks from starting cenobamate, the median reduction in monthly seizure frequency was 52.8% (IQR 27.1–80.3%); 22 (55.0%) participants had a ≥ 50% reduction in baseline seizure frequency and six (15.0%) reached seizure freedom. The median number of concomitant ASMs decreased from 3 (IQR 2–3) at baseline to 2 (IQR 2–3) at 12 weeks and the proportion of patients treated with > 2 concomitant ASMs decreased from 52.5% to 40.0%. Seven (17.5%) patients reported a total of 12 adverse events, 11 of which were considered adverse drug reactions to cenobamate.

Conclusion

In adults with uncontrolled focal seizures, the treatment with adjunctive cenobamate was well tolerated and was associated with improved seizure control and a reduction of the burden of concomitant ASMs.

Trial Registration Number

NCT05859854 (ClinicalTrials.gov Identifier).